Market Place
Sourcing Support
Altamira highlights RNA nanoparticles for osteoarthritis
13 Apr 2026 //
PHARMIWEB
Altamira Pharma Allows Japanese Patent For Bentrio Nasal Spray
13 Feb 2026 //
PHARMIWEB
Altamira Therapeutics To Present At mRNA Therapeutics Summit
23 Jan 2026 //
PHARMIWEB
Altamira Therapeutics Secures Swiss Market Approval for Bentrio
19 Dec 2025 //
PHARMIWEB
Altamira Therapeutics Announces Bentrio MDR Certification
20 Nov 2025 //
PHARMIWEB
Altamira Pharma Achieves DNA Molecule Delivery Via Nanoparticles
03 Nov 2025 //
PHARMIWEB
Altamira Therapeutics Updates Business Progress and Reveals H1
29 Aug 2025 //
PHARMAWEB
Altamira Therapeutics to Host First Half 2025 Financial Results
26 Aug 2025 //
PHARMAWEB
Altamira Therapeutics Collaborates on Circular RNA Delivery
27 May 2025 //
GLOBENEWSWIRE
Altamira Therapeutics Reports Full Year 2024 Financial Results
30 Apr 2025 //
GLOBENEWSWIRE
Altamira Receives USPTO Notice for Bentrio Nasal Spray Patent
07 Mar 2025 //
GLOBENEWSWIRE
Altamira, Partner On Radiopharmaceutical Targeting Strategies
22 Jan 2025 //
GLOBENEWSWIRE
Altamira Successfully Delivers Circular RNA via Nanoparticles
31 Dec 2024 //
GLOBENEWSWIRE
Altamira Announces Transition from NASDAQ to OTC Markets
20 Dec 2024 //
GLOBENEWSWIRE
Altamira Therapeutics Provides Update on Nasdaq Listing
04 Oct 2024 //
GLOBENEWSWIRE
Altamira Therapeutics Announces Extended ISO 13485 Certification
27 Sep 2024 //
GLOBENEWSWIRE
Altamira Therapeutics Provides Business Update, H1 2024 Results
24 Sep 2024 //
GLOBENEWSWIRE
Altamira To Host H1 2024 Results Call
20 Sep 2024 //
GLOBENEWSWIRE
Altamira Therapeutics Announces Closing Of Public Offering
19 Sep 2024 //
GLOBENEWSWIRE
Altamira Therapeutics Prices $12.0 Million Public Offering
17 Sep 2024 //
GLOBENEWSWIRE
Altamira Reports Enhanced Immunotherapy With Zbtb46 mRNA Delivery
12 Aug 2024 //
GLOBENEWSWIRE
Altamira Publishes Data On SOD2 mRNA Treatment For Aortic Aneurysm
19 Jul 2024 //
GLOBENEWSWIRE
Altamira Therapeutics Provides Business Update
28 May 2024 //
GLOBENEWSWIRE
Altamira: Patent For siRNA Nanoparticles In Cancer, Inflammation
01 May 2024 //
GLOBENEWSWIRE
Altamira Files Second Patent Application for OligoPhore Nanoparticles
24 Jan 2024 //
GLOBENEWSWIRE
Altamira Therapeutics Announces Collaboration with Heqet Therapeutics
05 Jul 2023 //
GLOBENEWSWIRE
Altamira Announces Publication of Article on Peptide-Based RNA Delivery
31 May 2023 //
ACCESSWIRE
Altamira SemaPhore Delivery Platform Shows Synergis-tic Effects of ZBTB46 mRNA
22 Mar 2023 //
GLOBENEWSWIRE
Altamira’s RNA Delivery Platform Drives Effective Treatment of Osteoarthritis
15 Mar 2023 //
ACCESSWIRE
Altamira Files Provisional Patent Application for OligoPhore Nanoparticles
27 Feb 2023 //
GLOBENEWSWIRE
Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit
10 Jan 2023 //
GLOBENEWSWIRE
